Program Overview

Introduction to the BridgeTech Program

The BridgeTech Program is a year-long national professional development program that helps researchers and entrepreneurs learn how to successfully navigate the medtech commercialisation pathway and bring products to market.

Program Overview

Convened and administered by QUT, the program is led by a collaborative consortium of medtech companies, universities, and industry associations. The program gives participants the skills and networks they need to succeed in the medtech industry through:

• Online training
• Webinars
• A speaker series
• A 3-day Symposium to meet the cohort and partners

Participation and Eligibility

Up to 80 people are selected to participate each year, and the program is accessible from anywhere in Australia. The program is open to entrepreneurs, medtech innovators, start-ups, and clinicians from across Australia.

History and Funding

Launched in 2018, the BridgeTech Program was awarded industry-matched funding through both MTPConnect's Project Fund Program and the Medical Research Future Fund's Biomedical Translation Bridge Program (BTB), and the Clinical Translation and Commercialisation Medtech (CTCM) Program until 2025.

Program Details

The program provides participants with the skills and networks needed to succeed in the medtech industry. The program includes a course outline, fees, and eligibility requirements, which are available for review.

Institutional Information

The program is convened and administered by QUT, which acknowledges the Traditional Owners of the lands where QUT now stands. QUT is registered with the following identifiers:

• TEQSA Provider ID: PRV12079 (Australian University)
• CRICOS No. 00213J
• ABN (Australian Business Number)